×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SNGX – soligenix, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SNGX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/2
07:48 am
sngx
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy [Yahoo! Finance]
Low
Report
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy [Yahoo! Finance]
4/2
07:48 am
sngx
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy [TheStreet.com]
Low
Report
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy [TheStreet.com]
4/2
07:30 am
sngx
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Medium
Report
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
3/31
07:40 am
sngx
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results [Yahoo! Finance]
Medium
Report
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results [Yahoo! Finance]
3/31
07:30 am
sngx
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Medium
Report
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
3/26
07:30 am
sngx
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Medium
Report
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
3/25
01:52 am
sngx
Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting [Yahoo! Finance]
Low
Report
Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting [Yahoo! Finance]
3/23
08:00 am
sngx
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 [Yahoo! Finance]
Low
Report
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/31
04:06 pm
sngx
Form 10-K SOLIGENIX, INC. For: Dec 31
Low
Report
Form 10-K SOLIGENIX, INC. For: Dec 31
2/17
09:37 pm
sngx
Form SCHEDULE 13G/A SOLIGENIX, INC. Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SCHEDULE 13G/A SOLIGENIX, INC. Filed by: ARMISTICE CAPITAL, LLC
2/12
04:06 pm
sngx
Form 8-K SOLIGENIX, INC. For: Feb 12
Low
Report
Form 8-K SOLIGENIX, INC. For: Feb 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/3
Form 8-K SOLIGENIX, INC. For: Jan 02
26.2%
3/19 Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma 20.5%
5/14 Form 10-Q SOLIGENIX, INC. For: Mar 31 12.3%
7/26 Form DEF 14A SOLIGENIX, INC. For: Sep 06 12.3%
3/30 Form 10-K SOLIGENIX, INC. For: Dec 31 12.0%
12/13 Form 4 SOLIGENIX, INC. For: Dec 12 Filed by: Donini Oreola 10.9%
7/8 Soligenix Announces Appointment of Diane L. Parks to its Board of Directors 9.5%
10/3 Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada 7.7%
7/10 Form 4 SOLIGENIX, INC. For: Jun 28 Filed by: Pearson Mark E. 7.6%
9/17 Form 8-K SOLIGENIX, INC. For: Sep 16 6.6%
3/19 Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma 20.5%
5/14 Form 10-Q SOLIGENIX, INC. For: Mar 31 12.3%
7/26 Form DEF 14A SOLIGENIX, INC. For: Sep 06 12.3%
3/30 Form 10-K SOLIGENIX, INC. For: Dec 31 12.0%
12/13 Form 4 SOLIGENIX, INC. For: Dec 12 Filed by: Donini Oreola 10.9%
7/8 Soligenix Announces Appointment of Diane L. Parks to its Board of Directors 9.5%
10/3 Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada 7.7%
7/10 Form 4 SOLIGENIX, INC. For: Jun 28 Filed by: Pearson Mark E. 7.6%
9/17 Form 8-K SOLIGENIX, INC. For: Sep 16 6.6%
TOP News Decliners
3/23
Soligenix and University of Hawai?i at Manoa Initiate Work on Novel Coronavirus Vaccine for COVID-19
-30.0%
4/6 Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma -20.0%
4/16 Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals -15.8%
4/30 Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma -11.4%
8/29 Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference -10.1%
3/19 Solgenix up 16% premarket on positive SGX301 data [Seeking Alpha] -10.0%
12/7 Soligenix, Inc. (NASDAQ: SNGX) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -9.3%
4/20 Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity [Seeking Alpha] -8.1%
8/13 Form 10-Q SOLIGENIX, INC. For: Jun 30 -8.0%
12/12 Soligenix initiates clinical trial of heat stable ricin toxin vaccine [Seeking Alpha] -7.5%
4/6 Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma -20.0%
4/16 Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals -15.8%
4/30 Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma -11.4%
8/29 Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference -10.1%
3/19 Solgenix up 16% premarket on positive SGX301 data [Seeking Alpha] -10.0%
12/7 Soligenix, Inc. (NASDAQ: SNGX) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -9.3%
4/20 Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity [Seeking Alpha] -8.1%
8/13 Form 10-Q SOLIGENIX, INC. For: Jun 30 -8.0%
12/12 Soligenix initiates clinical trial of heat stable ricin toxin vaccine [Seeking Alpha] -7.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: